|
|
|
|
HIV-thrombocytopenia therapy infusion fraud: Miami Physician Sentenced to 97 Months in Prison for Role in $10
Miami physician Roberto Rodriguez, 54, was sentenced today to 97 months in prison for his role in a Medicare fraud scheme involving HIV infusion services, announced Assistant Attorney General Lanny A.Breuer of the Criminal Division,...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
- Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention)...
|
|
|
New peripherally inserted central catheter mimics nature
A novel coating being used on a new peripherally inserted central catheter (PICC) from r4 Vascular mimics the cell layer found on natural tissue surfaces.r4 Vascular designed the catheter to have a biomimetic surface that mimics the...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
(GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the EMINENCE (Evaluation of M118 in Percutaneous...
|
|
|
SVG occlusion not linked to anti-heparin/PF4 antibodies
MedWire News: Antibodies to heparin and platelet factor 4 (PF4) complexes are not independently associated with early saphenous vein graft (SVG) occlusion or adverse clinical outcomes after coronary artery bypass graft (CABG) surgery, US...
|
|
|
Momenta Pharmaceuticals (MNTA) Announces Results From the M118 EMINENCE Trial
Momenta Pharmaceuticals, Inc.(Nasdaq: MNTA) announced top-line results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) phase 2 multicenter study of the intravenous formulation of M118. EMINENCE was designed...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.(Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
(GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.(Nasdaq:MNTA - News), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the EMINENCE (Evaluation of M118...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
(GlobeNewswire via COMTEX) -- MNTA | Quote | Chart | News | PowerRating -- Momenta Pharmaceuticals, Inc.(Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118
EMINENCE was designed to evaluate the safety and feasibility of utilizing M118 as an anticoagulant in the target population of patients with stable coronary artery disease (CAD) undergoing a percutaneous coronary intervention (PCI).
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
(GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.(Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the EMINENCE (Evaluation of M118 in...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
EMINENCE Phase 2 Trial Achieves Primary Endpoint Press Release Source: Momenta Pharmaceuticals Buzz up!Companies: CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc! (Nasdaq:MNTA - News), a biotechnology...
|
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
(GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc.(Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the EMINENCE (Evaluation of M118 in...
|
|
|
Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Car
aDepartment of Breast Medical Oncology, The University of Texas M.D.Anderson Cancer Center, Houston, Tex., and bSection of Medical Oncology, The University of Texas Medical Branch, Galveston, Tex., USA Key Words Advanced breast cancer...
|
|
|
S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer
bEndoscopy and Endoscopic Surgery, Faculty of Medicine, University of Tokyo, cDepartment of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan Oncology 2009;77:71-74 (DOI: 10.1159/000226214) Key Words S-1 Biliary tract cancer...
|
|
|
Organism-specific platelet response and factors affecting survival in thrombocytopenic very low birth weight b
To study organism-specific platelet response and factors affecting survival in thrombocytopenic very low birth weight (VLBW) babies with sepsis.Very low birth weight babies (birth weight <1500 g) admitted to a single level-three...
|
|
|
The Medicines Company Extends Exclusivity for Anticoagulant to September 2010
FDA has granted The Medicines Company pediatric exclusivity for Angiomax, an anticoagulant, for another six months.The agency will thus not authorize commercialization of generic versions prior to September 2010. The Medicines Company...
|
|
|
Studies offer contradictory data for carboplatin plus liposomal doxorubicin in ovarian cancer
Two studies presented at ASCO this year demonstrated mixed results on the use of carboplatin plus pegylated liposomal doxorubicin in the treatment of patients with ovarian cancer.Data from the Multicenter Italian Trials in Ovarian Cancer...
|
|
|
Four Miami-Area Residents Sentenced In $10 Million Medicare Fraud Scheme
Four Miami-area residents were sentenced today in connection with a $10 million Medicare fraud scheme involving HIV infusion clinics, Assistant Attorney General Lanny A.Breuer of the Criminal Division and U.S. Attorney R. Alexander...
|
|
|
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leuke
Grade 2 to 4 neutropenia and/or thrombocytopenia occurred in 94 (72%) pts during dasatinib therapy Grade 3 to 4 occurred in 67 (52%) pts Of the 94 pts who developed grade 2 to 4 neutropenia and/or thrombocytopenia- 68% also...
|
|
|
Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic revi
Print Save in My Library Free Abstract Ribic C et al.- Low-molecular-weight heparin may be effective for thromboprophylaxis in medical-surgical critically ill patients, but no trials have compared LMWH against an alternative active...
|
|
|
Romiplostim Improves Platelet Counts in Nonsplenectomised Patients With Immune Thrombocytopenia: Presented at
-- Romiplostim significantly reduces the incidence of splenectomy and of grade 3 or higher bleeding events in the treatment of nonsplenectomised patients with immune thrombocytopenia (ITP), while demonstrating a similar safety profile...
|
|
|
EHA 2009: Romiplostim in Immune Thrombocytopenia Prevents Splenectomy
_ EHA 2009: Romiplostim in Immune Thrombocytopenia Prevents Splenectomy.
|
|
|
EHA 2009: Romiplostim in Immune Thrombocytopenia Prevents Splenectomy
_ EHA 2009: Romiplostim in Immune Thrombocytopenia Prevents Splenectomy.
|
|
|
New Dasatinib Dosing Schedule Improves Safety Profile
A new dosing schedule for dasatinib for some patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to imatinib improves the safety profile of the drug while maintaining efficacy, according to a review of dasatinib...
|
